LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.58

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.5699999999999998

Max

1.6099999999999999

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
EPS	-0.43
Gewinnspanne	-2,190.837
Angestellte	171
EBITDA	19M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+91.08% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6M 96M
Vorheriger Eröffnungskurs	1.58
Vorheriger Schlusskurs	1.58

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Nov. 2025, 17:44 UTC

Ergebnisse

Wichtige Markttreiber

Deere Warns of Tough Year Ahead as Earnings, Sales Fall -- Update

27. Nov. 2025, 00:00 UTC

Market Talk

Rio Tinto's Coming Investor Briefing Seen Focused on Costs, Lithium, Asset Sales -- Market Talk

26. Nov. 2025, 23:47 UTC

Market Talk

Nikkei May Rise as Fears About Potential AI Bubble Ease -- Market Talk

26. Nov. 2025, 23:28 UTC

Market Talk

Mortgage Refinancing in New Zealand Will Spur Recovery -- Market Talk

26. Nov. 2025, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. Nov. 2025, 23:21 UTC

Market Talk

RBNZ Rate Cuts Finally Getting Traction With Consumers -- Market Talk

26. Nov. 2025, 23:02 UTC

Market Talk

Steelmaking Coal Price Signal Knocked by China Import Shift -- Market Talk

26. Nov. 2025, 21:38 UTC

Ergebnisse

These Stocks Moved the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. Nov. 2025, 21:25 UTC

Ergebnisse

Li Auto Posts Surprise Loss, Stock Rises. What's Next for Its Diving EV Sales. -- Barrons.com

26. Nov. 2025, 21:17 UTC

Akquisitionen, Fusionen, Übernahmen

Commercial Metals Co Announces Closing of $2B Senior Notes Offering

26. Nov. 2025, 21:16 UTC

Ergebnisse

Deere Beat Earnings Estimates. Why the Stock Is Falling. -- Barrons.com

26. Nov. 2025, 21:09 UTC

Ergebnisse

Roblox Isn't Playing Games. Why the Stock Could -2-

26. Nov. 2025, 21:09 UTC

Ergebnisse

Roblox Isn't Playing Games. Why the Stock Could Jump 50%. -- Barrons.com

26. Nov. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. Nov. 2025, 20:25 UTC

Akquisitionen, Fusionen, Übernahmen

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. Nov. 2025, 20:15 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. Nov. 2025, 20:08 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

26. Nov. 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Settles Higher Ahead of Holiday -- Market Talk

26. Nov. 2025, 19:30 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. Nov. 2025, 19:21 UTC

Akquisitionen, Fusionen, Übernahmen

Teck Resources: ISS and Glass Lewis Recommend Teck Hldrs Vote for Anglo American Deal

26. Nov. 2025, 18:43 UTC

Market Talk

U.S. Natural Gas Storage Down for Second Straight Week -- Market Talk

26. Nov. 2025, 18:41 UTC

Market Talk

U.S. Oil Rig Count Falls By 12 to 407 -- Market Talk

26. Nov. 2025, 18:19 UTC

Ergebnisse

Workday Beat Earnings Estimates. The Stock Is Down 10% Anyway. -- Barrons.com

26. Nov. 2025, 17:51 UTC

Ergebnisse

Deere Forecasts Higher Tariff Costs, Less Profit in 2026 -- WSJ

26. Nov. 2025, 17:50 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. Nov. 2025, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

26. Nov. 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. Nov. 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

26. Nov. 2025, 17:16 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Blue Owl Is Having a Rough Year. Its Co-CEO Says -2-

26. Nov. 2025, 17:16 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Blue Owl Is Having a Rough Year. Its Co-CEO Says Investors' Fears Are 'Ungrounded.' -- Barrons.com

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

91.08% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD 91.08%

Hoch 4 USD

Tief 2 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.